Merck's top cancer team basks in the warm light of positive Keytruda data from a landmark study for hard-to-treat breast cancer
BARCELONA — While Bristol-Myers Squibb execs spent much of the weekend in Barcelona trying to explain the more positive aspects of recent data on Opdivo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
